Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.7
4.6
Journals
Antibiotics
Special Issues
Antimicrobial Agents for Drug-Resistant Infections: From Identification to Preclinical and...
share announcement

Antimicrobial Agents for Drug-Resistant Infections: From Identification to Preclinical and Clinical Trials

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Novel Antimicrobial Agents".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 122

Special Issue Editors

Prof. Dr. Javier Eduardo García Castañeda

E-Mail Website
Guest Editor
Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá Carrera 45 No 26-85, Building 450, Bogotá 11321, Colombia
Interests: peptide synthesis; antimicrobial and anticancerigenic peptides; glycopeptides; organometallic peptides
Special Issues, Collections and Topics in MDPI journals
Dr. Zuly Jenny Rivera-Monroy

E-Mail Website
Guest Editor
Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá Carrera 45 No 26-85, Building 451, Bogotá 11321, Colombia
Interests: peptide synthesis; peptide therapeutic application; peptide analysis by HPLC and MS
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug resistance, in both antimicrobial and anticancer therapies, arises when pathogens or cancer cells become less susceptible to drugs, reducing treatment efficacy. This growing health threat requires urgent multisectoral action to achieve the Sustainable Development Goals (SDGs) and imposes a significant economic burden due to prolonged hospital stays, higher healthcare costs, and premature mortality.

Multidrug-resistant and pan-resistant bacterial strains, causing infections untreatable with current antibiotics, are a critical concern. According to the World Health Organization (WHO), the clinical development pipeline for new antimicrobials is severely depleted. A 2019 report found that of 32 antibiotics in development, only 6 were considered innovative, underscoring the need for novel therapeutic approaches.

Peptides, both antimicrobial and anticancer, have emerged as promising alternatives due to their synthetic flexibility, favorable safety profiles, and lower propensity to induce resistance compared to small-molecule drugs.

This Special Issue seeks to compile research on identifying new antimicrobial and anticancer agents, including proteins, peptides, and amino acids, with or without non-protein components such as organic moieties, sugars, lipids, and organometallic compounds. Multidisciplinary strategies to discover bioactive molecules are essential for expanding therapeutic options capable of overcoming drug resistance and restoring treatment efficacy.

Prof. Dr. Javier Eduardo García Castañeda
Dr. Zuly Jenny Rivera-Monroy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobials agents
  • drug resistant
  • anti-cancerogenic agents
  • drug development
  • preclinical trials
  • clinical trials
  • pharmaceutical optimization

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

26 pages, 1978 KiB  
Article
Fluorescent Peptides Internalize HeLa Cells and Kill Multidrug-Resistant Clinical Bacterial Isolates
by Daniel Castellar-Almonacid, Kelin Johana Cuero-Amu, Jose David Mendoza-Mendoza, Natalia Ardila-Chantré, Fernando José Chavez-Salazar, Andrea Carolina Barragán-Cárdenas, Jhon Erick Rivera-Monroy, Claudia Parra-Giraldo, Zuly Jenny Rivera-Monroy, Javier García-Castañeda and Ricardo Fierro-Medina
Antibiotics 2025, 14(8), 793; https://doi.org/10.3390/antibiotics14080793 (registering DOI) - 4 Aug 2025
Abstract
Palindromic antimicrobial peptides (PAMs) constitute versatile scaffolds for the design and optimization of anticancer agents with applications in therapy, diagnosis, and/or monitoring. In the present study, fluorolabeled peptides derived from the palindromic sequence RWQWRWQWR containing fluorescent probes, such as 2-Aminobenzoyl, 5(6)-Carboxyfluorescein, and Rhodamine [...] Read more.
Palindromic antimicrobial peptides (PAMs) constitute versatile scaffolds for the design and optimization of anticancer agents with applications in therapy, diagnosis, and/or monitoring. In the present study, fluorolabeled peptides derived from the palindromic sequence RWQWRWQWR containing fluorescent probes, such as 2-Aminobenzoyl, 5(6)-Carboxyfluorescein, and Rhodamine B, were obtained. RP-HPLC analysis revealed that the palindromic peptide conjugated to Rhodamine B (RhB-RWQWRWQWR) exhibited the presence of isomers, likely corresponding to the open-ring and spiro-lactam forms of the fluorescent probe. This equilibrium is dependent on the peptide sequence, as the RP-HPLC analysis of dimeric peptide (RhB-RRWQWR-hF-KKLG)2K-Ahx did not reveal the presence of isomers. The antibacterial activity of the fluorescent peptides depends on the probe attached to the sequence and the bacterial strain tested. Notably, some fluorescent peptides showed activity against reference strains as well as sensitive, resistant, and multidrug-resistant clinical isolates of E. coli, S. aureus, and E. faecalis. Fluorolabeled peptides 1-Abz (MIC = 62 µM), RhB-1 (MIC = 62 µM), and Abz-1 (MIC = 31 µM) exhibited significant activity against clinical isolates of E. coli, S. aureus, and E. faecalis, respectively. The RhB-1 (IC50 = 61 µM), Abz-1 (IC50 = 87 µM), and RhB-2 (IC50 = 35 µM) peptides exhibited a rapid, significant, and concentration-dependent cytotoxic effect on HeLa cells, accompanied by morphological changes characteristic of apoptosis. RhB-1 (IC50 = 18 µM) peptide also exhibited significant cytotoxic activity against breast cancer cells MCF-7. These conjugates remain valuable for elucidating the possible mechanisms of action of these novel anticancer peptides. Rhodamine-labeled peptides displayed cytotoxicity comparable to that of their unlabeled analogues, suggesting that cellular internalization constitutes a critical early step in their mechanism of action. These findings suggest that cell death induced by both unlabeled and fluorolabeled peptides proceeds predominantly via apoptosis and is likely contingent upon peptide internalization. Functionalization at the N-terminal end of the palindromic sequence can be evaluated to develop systems for transporting non-protein molecules into cancer cells. Full article
(This article belongs to the Special Issue Antimicrobial Agents for Drug-Resistant Infections: From Identification to Preclinical and Clinical Trials)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop